CVSA Stock Forecast & Price Target

Covista Inc. has demonstrated a robust growth trajectory, with a significant 19% increase in new undergraduate enrollment in 2009, largely benefiting from economic conditions and rising unemployment. The company's proactive focus on operations and capital return has led to impressive enrollment growth at its Chamberlain and Walden institutions, with rates of 18% and 38% respectively expected between 2022 and 2025. Additionally, expanding EBITDA margins driven by operating leverage from enrollment growth suggest that Covista's financial health remains strong, potentially enhancing profitability as the company scales its campus operations through FY29.

Covista Inc. has experienced a significant decline in stock performance, underperforming the S&P by 22 points over the past six months, primarily due to a notable decrease in new student enrollments at its Chamberlain campus, which management attributes to an ineffective marketing strategy. Additionally, the company's forward EV/EBITDA multiple has fallen from approximately 12x to 8.6x, indicating a deterioration in market perception and valuation. The overall stagnation in post-secondary enrollment, evidenced by a ~1% CAGR decline over the past five years amidst increasing competition and regulatory challenges, further compounds the financial pressures facing Covista and contributes to a negative outlook.